Back to top
more

Intersect ENT, Inc. (XENT)

(Delayed Data from NSDQ)

$33.65 USD

33.65
406,200

+1.22 (3.76%)

Updated May 3, 2019 04:00 PM ET

After-Market: $33.66 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Implied Volatility Surging for Intersect ENT (XENT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.

Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS

by Zacks Equity Research

This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.

Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

by Zacks Equity Research

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Intersect ENT (XENT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Intersect ENT

by Zacks Equity Research

Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Intersect Posts Preliminary Q1 Results, Withdraws '20 View

by Zacks Equity Research

Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.

Intersect ENT (XENT) Down 49.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for March 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Intersect ENT Down on Low Propel Sales, Pricing Pressure

by Zacks Equity Research

Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.

Implied Volatility Surging for Intersect ENT (XENT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.

Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.

Intersect ENT (XENT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intersect ENT (XENT) delivered earnings and revenue surprises of 28.57% and 2.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

New Product Suite Boosts Intersect ENT Despite Cost Concerns

by Zacks Equity Research

With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?

by Zacks Equity Research

Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.

Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?

by Zacks Equity Research

Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.

Here's Why You Should Hold on to Intersect ENT (XENT) for Now

by Zacks Equity Research

Investors can retain Intersect ENT (XENT) stock for now, courtesy of its solid prospects.

Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

by Zacks Equity Research

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

Intersect ENT (XENT) Grows on Innovation Despite Cost Woes

by Zacks Equity Research

The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.

Why Is Intersect ENT (XENT) Up 21.7% Since Last Earnings Report?

by Zacks Equity Research

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates

by Zacks Equity Research

Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.

Intersect ENT (XENT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intersect ENT (XENT) delivered earnings and revenue surprises of -2.50% and -0.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.